The Future of Progressive Multiple Sclerosis Therapies

• Published in: Federal practitioner Vol. 37; no. Suppl 1; pp. S43 - S49
• Main Authors: Hollen, Chris W, Paz Soldán, M Mateo, Rinker, 2nd, John R, Spain, Rebecca I
• Format: Journal Article
• Language: English
• Published: United States Frontline Medical Communications Inc 01.04.2020
• ISSN: 1078-4497; 1945-337X

Multiple sclerosis (MS) affects more than a million people in the US. A considerable portion of these patients either begin with primary progressive disease or eventually transition to secondary progressive MS. A progressive disease course is the most critical factor affecting disability accumulation. The relatively recent development of treatments for relapsing multiple sclerosis has had a profound impact on the disease course for many with MS. Unfortunately, therapies for progressive MS have not had the same degree of advancement in general. New insights into the pathophysiology of progressive MS may lead to new treatments. In this review, we identify some of the significant challenges encountered in the development of therapies for progressive MS, assess the evidence for use of currently approved therapies for patients with progressive MS, identify some of the current therapies in development from progressive MS, and consider the role for discontinuing therapy in certain patients. Developing effective disease modifying therapies that slow or stop the gradual accumulation of neurologic disability in progressive MS represents a critical unmet need. As the understanding of the inflammatory and neurodegenerative aspects of MS are better elucidated there may be opportunity for advancement in the treatment of progressive MS.